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Abstract
The interaction with bone marrow (BM) plays a crucial role in pathophysiological features of multiple myeloma (MM),
including cell proliferation, chemoresistance, and bone lesion progression. To characterize the MM-BM interactions, we
utilized an in vivo experimental model for human MM in which a GFP-expressing human MM cell line is transplanted into
NOG mice (the NOG-hMM model). Transplanted MM cells preferentially engrafted at the metaphyseal region of the BM
endosteum and formed a complex with osteoblasts and osteoclasts. A subpopulation of MM cells expressed VE-cadherin
after transplantation and formed endothelial-like structures in the BM. CD138
+ myeloma cells in the BM were reduced by
p53-dependent apoptosis following administration of the nitrogen mustard derivative bendamustine to mice in the NOG-
hMM model. Bendamustine maintained the osteoblast lining on the bone surface and protected extracellular matrix
structures. Furthermore, bendamustine suppressed the growth of osteoclasts and mesenchymal cells in the NOG-hMM
model. Since VE-cadherin
+ MM cells were chemoresistant, hypoxic, and HIF-2a-positive compared to the VE-cadherin
2
population, VE-cadherin induction might depend on the oxygenation status. The NOG-hMM model described here is a
useful system to analyze the dynamics of MM pathophysiology, interactions of MM cells with other cellular compartments,
and the utility of novel anti-MM therapies.
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Introduction
Multiple myeloma (MM) is a clonal disorder of late-stage B cells,
in which transformed plasma cells expand and accumulate in the
bone marrow (BM), leading to cytopenia, bone resorption and the
production of the characteristic monoclonal immunoglobulin [1].
The bone marrow (BM) is believed to play a crucial role in the
pathophysiological features of MM, including cell proliferation,
chemoresistance and bone lesion progression. The ‘‘MM niche’’ is
composed of osteoblasts, osteoclasts, vascular endothelial cells,
stromal cells, adipocytes, and extracellular matrix (ECM) proteins
[2]. MM cells are thought to be maintained by these various
stromal cells [3], which regulate their survival, proliferation and
apoptosis. However, the cellular and anatomical features of
stromal cells have not been thoroughly examined in the MM. In
this study, the MM niche was characterized in the BM of a mouse
transplanted with human MM cells.
Recently, chemotherapeutic strategies for the treatment of MM
have significantly advanced, including the development of anti-
angiogenic drugs [4]. Using the MM mouse model, the suppressive
effects of bendamustine, a bifunctional chemotherapeutic agent
with a nitrogen mustard structure and a purine benzimidazole
ring, were examined. Because of its unique structure, bendamus-
tine exhibits only partial cross-resistance with other alkylators [5–
7] and is widely used for the treatment of various hematological
malignancies, including low-grade lymphoma and MM [8,9].
Although the clinical utility of bendamustine in the treatment of
MM has been clearly demonstrated [10,11], the specific cellular
and molecular effects of bendamustine on MM cells and the MM
niche in vivo have not been determined. Therefore, this issue was
investigated in a mouse model of human MM.
Results
Establishment of a human multiple myeloma in NOD/
SCID/cc
null mice
When U266 cells, a human IgE-producing myeloma cell line,
were transplanted into super-immunodeficient NOG mice [12],
the cells engrafted and proliferated in the BM but not in any other
organs. These mice exhibited various MM clinical symptoms,
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30557including the development of osteolytic bone lesions [13]. To
analyze the myeloma niche more precisely, U266 cells stably
expressing EGFP (U266-GFP) were transplanted into NOG mice
(NOG-hMM model). 2610
6 U266-GFP cells were intravenously
inoculated into irradiated NOG mice (2.4 Gy), and recipient mice
were sacrificed 2–6 weeks after transplantation to assess the
establishment of the MM (Fig. 1A). After 4 weeks, the recipient
NOG mice all developed bilateral paralysis and pathological
fractures. Radiologic examination revealed severe scoliosis
(Fig. 1B). Because GFP fluorescence in transplanted U266-GFP
cells tended to decrease in vivo (data not shown), we used CD138, a
pan-myeloma marker, to detect U266-GFP cells. Flow cytometric
analysis of the BM revealed myeloma cells positive for human
CD138 and negative for mouse CD45 (Fig. 1C). Furthermore,
human IgE was detected in the sera of recipient mice at 5 days
after transplantation and was drastically increased at day 35 post-
transplantation (Fig. 1D).
The human MM niche in the BM of NOG mice
Engraftment of GFP-positive myeloma cells was detected in the
BM but not in the spleen, liver, or any other organs (Fig. 1E). To
characterize the myeloma niche in vivo, the recipient long bones,
including the femur and tibia, were analyzed because their
anatomical and histological structures in the hematopoietic niche
have been well characterized. Within the BM of the long bone,
myeloma cells were located mainly in the endosteal zone in the
femur (Fig. 1E), indicating that the endosteal zone of the BM is the
preferential location for myeloma engraftment. Next, the temporal
distribution of myeloma cells in the BM was investigated. At the
early stage (2–4 weeks after transplantation), myeloma cells were
Figure 1. Interaction between multiple myeloma cells and the niche in an in vivo human myeloma model. A. Study design of the NOG-
hMM model. Two million EGFP
+ U266 myeloma (U266-EGFP) cells were intravenously inoculated into 2.4 Gy irradiated NOG (NOD/SCID/gc
null) mice.
Two to six weeks after transplantation, mice were sacrificed for analysis. B. Representative clinical manifestation (upper panel) and radiologic
examination (lower panel) of mice 4 weeks after transplantation. All mice showed hind leg paralyses (left) associated with spinal compression
fractures (left; arrow). This clinical manifestation was observed in more than 20 mice. C. Representative FACS plot of U266-EGFP cell-transplanted
NOG mice. Bone marrow of NOG mice was analyzed by FACS 4 weeks after U266-EGFP cell transplantation using anti-human CD138 antibody and
anti-murine CD45 antibody. The experiment was performed in more than forty mice with similar results. D. Serum levels of human IgE. Human IgE
levels in the serum of NOG mice at 0 (non-transplanted, non-irradiated mice), 5 or 35 days after transplantation with U266-EGFP cells were analyzed
by ELISA (n=3–5, mean6SD). The experiment was performed twice with similar results. E. Double immunohistochemistry (IHC) of EGFP (green) and
TOTO3 (blue) of the BM (upper panels), spleen or liver (lower panels) at 2 weeks after transplantation. U266-EGFP cells engrafted only in the BM.
Representative data from 10 to 20 fields from the BM of two mice from three independent experiments are shown. Bars=200 mm. F.
Immunohistochemical (IHC) analysis of EGFP (green) and TOTO3 (blue) at the anatomical region of long bones at the early stage. Representative data
from 10 to 20 fields from the BM of two mice from three independent experiments are shown. Bars=200 mm. G. Quantification of U266-EGFP cells at
the diaphysis and the metaphysis of the long bones. U266-EGFP at the metaphysis regions is represented relative to the diaphysis region
(diaphysis=100, n=3, mean 6 SEM). The experiment was performed twice with similar results.
doi:10.1371/journal.pone.0030557.g001
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a long bone adjacent to the epiphyseal plate) but not in the
epiphyseal region (the rounded end of a long bone) or the
diaphyseal region (the mid-section of a long bone) of the BM
(Fig. 1F). CD138
+ myeloma cells at the later stage (4–9 weeks after
transplantation) were distributed mainly in the metaphyseal region
and were relatively rare in the diaphyseal region in the femur
(Fig. 1G).
Immunohistochemical analysis of the MM component at the
early stage (2 weeks after transplantation) revealed that GFP-
positive myeloma cells formed a complex with alkaline phospha-
tase (ALP)-positive osteoblasts and matrix metalloprotease (MMP)
9-positive osteoclasts in the femoral endosteum (Fig. 2A). Under
normal conditions, NOG mice possess more tartrate-resistant acid
phosphatase (TRAP)-positive osteoclasts in the metaphyseal region
than in the diaphyseal region in the femur (Fig. 2B, left panels). At
4 weeks after transplantation, increased TRAP activity, which
represents an increase in osteoclasts, was observed in the
metaphyseal region but not in the femoral diaphyseal region
(Fig. 2B, right panels). These data suggest that the myeloma niche
is located in the metaphyseal endosteal zone of the longitudinal
bone and is composed of osteoblasts and osteoclasts in vivo.
VE-cadherin expression and vascular mimicry of the MM
cells
It is well known that increased vasculature accompanies active
myeloma [14–16]. Therefore, the relationship between endothelial
and myeloma cells was analyzed. Flow cytometric analysis
revealed a VE-cadherin
+ subpopulation of human CD138
+
myeloma cells in vivo (Fig. 3A). Interestingly, these VE-cadherin
+
cells were not detected in vitro and were only observed after the
transplantation of U266-GFP cells into NOG mice (Fig. 3A).
These VE-cadherin
+ cells formed vascular-like structures in the
femoral BM (Fig. 3B). To further characterize the VE-cadherin
+
cell population, VE-cadherin
+ cells and VE-cadherin
2 cells were
sorted from the CD138
+ fraction and the expression of
angiogenesis-related genes in each subpopulation was analyzed
using human-specific primer sets. MM cells have been reported to
secrete vascular endothelial growth factor (VEGF)-A into the BM
microenvironment to induce angiogenesis [17]. Consistent with
previous reports, human interleukin (IL)-6, VEGF-A, and
fibroblast growth factor (FGF)-2 were expressed in both fractions
(Fig. 3C–E). In particular, the expression of FGF-2 was
significantly increased in the VE-cadherin
+ fraction (Fig. 3E).
These data suggest that FGF-2 is involved in myeloma
angiogenesis and may induce the formation of vascular endothe-
lial-like structures by a subpopulation of VE-cadherin
+ cells.
Although it is rare, human cancer cells are known to sometimes
fuse with endothelial cells to form hybrid cells [18]. To address this
possibility, fluorescence in situ hybridization (FISH) analysis was
performed on the VE-cadherin
+ and VE-cadherin
2 CD138
+ cells
from NOG-hMM mice. Cultured U266-GFP cells were used as a
negative control. Fused cells were very rare (,0.1%) and not
specific to the VE-cadherin
+ subpopulation (Table S1). These data
indicate that human VE-cadherin
+ CD138
+ cells were generated
in the BM microenvironment in vivo.
In vivo effect of bendamustine
Using the NOG-hMM model, the antitumor effect of
bendamustine was assessed in vivo. A single dose (Fig. 4A) or two
doses over the course of a week (Fig. 4B) of bendamustine (20 mg/
kg) were injected intraperitoneally into myeloma-inoculated NOG
mice 5 days after transplantation, at which point MM cells had
already engrafted into the BM. These mice were analyzed at 4–6
weeks after administration (Fig. 4A) or when the mice had
developed symptoms (Fig. 4B). At the early stage after transplan-
tation, myeloma cells were only observed at the metaphyseal
region of the BM (Fig. 1F). However, in the later stage (Fig. 4C
left), at which time the recipient mice were treated with
bendamustine, myeloma cells had infiltrated the diaphyseal zone
of the bone. In response to sequential bendamustine administra-
tion, femoral diaphyseal myeloma cells were largely depleted
(Fig. 4C). In non-treated mice, myeloma cells accumulated in the
metaphyseal region rather than in the diaphyseal region of the
femur (Fig. 4D, left). Although bendamustine treatment largely
depleted the MM cells (Fig. 4D, right), there were some instances
of bendamustine-resistant myeloma cells which were positive for
VE-cadherin (Fig. 4E).
Remaining VE-cadherin
+ MM cells express HIF-2a in
response to hypoxia
The hypoxic status of the BM is an important niche
characteristic [19]. The hypoxia-inducible transcription factor
HIF-2a is known to induce VE-cadherin expression [20].
Therefore, levels of the hypoxic marker pimonidazole and levels
of HIF-1a and HIF-2a were compared between the VE-cadherin
+
and VE-cadherin
2 MM fractions. The expression level of HIF-2a
was higher in the VE-cadherin
+ cell fraction than in the VE-
cadherin
2 cell fraction, and, interestingly, was induced after
transplantation into NOG mice (Fig. 4F). VE-cadherin
+ MM cells
showed higher levels of pimonidazole and HIF-1a protein than
VE-cadherin
2 MM cells (Fig. 4G, H). These data indicate that the
HIF-2a-VE-cadherin pathway is activated by hypoxia in a subset
of MM cells.
The effect of bendamustine treatment on the paracrine loop of
angiogenic factors was also examined in vivo. Human VEGFA and
IL-6 transcript levels were significantly reduced after bendamus-
tine treatment, but FGF-2 transcript levels remained unchanged
(Fig. 4I). These results indicate that bendamustine could suppress
myeloma cells and affect the myeloma niche by inhibiting VEGFA
and IL-6 production.
Characterization of the extracellular matrix components
and mesenchymal cells in the MM niche
To further characterize the myeloma niche, the expression
and structure of the extracellular matrix (ECM) components of
the BM, including fibronectin, type IV collagen (col IV) and a-
laminin, were analyzed. Metaphyseal MM BM of the femur
showed disruption of each of these ECM components (Fig. 5B,
right; 5D, right; 5F, right). In addition, ECM structures in the
non-MM diaphyseal areas of the femur were increased and
disorganized compared to normal NOG mice (Fig. 5A–F). The
presence of another component of the BM, nestin
+ mesenchymal
cells [21], was also examined in myeloma. While nestin
+ cells
were rare in the femoral BM of normal NOG mice (Fig. 5G,
top), nestin
+ cells were drastically increased in the femoral BM of
MM mice (Fig. 5G, middle). Interestingly, CD138
+ MM cells
were located in close contact with nestin
+ cells (Fig. 5G, middle).
Moreover, nestin
+ cells in NOG-hMM mice were increased in
the non-MM areas of the femoral BM (Fig. 5G, bottom).
Although nestin
+ cells are normally located adjacent to the
vasculature [21], nestin
+ cells in NOG-hMM mice did not co-
localize with endothelial cells (Fig. 5H). These data suggest that
myeloma cells promote ECM reorganization and nestin
+ cell
proliferation, which might create an abnormal microenviron-
ment that promotes tumor progression and drug resistance in
MM.
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suppresses pathological myelofibrosis
After a single bendamustine treatment, the osteoblast lining on
the femoral surface of the treated mice, which was disrupted
without treatment, was observed to be intact (Fig. 6A). TRAP
staining of single bendamustine-treated mice showed a decrease in
the number and size of osteoclasts compared to PBS-treated (non-
treated) mice (Fig. 6B), while bendamustine had no direct effect on
osteoclast numbers (data not shown). ECM structures of the
femoral BM, such as fibronectin, col IV and a-laminin, were
maintained by single bendamustine treatment (Fig. 6C–E).
Moreover, treatment with bendamustine also suppressed the
Figure 2. Dynamics of osteoblasts and osteoclasts at the MM niche. A. Triple IHC of GFP (green), ALP (blue) and MMP-9 (red) in the
metaphyseal region at 2 weeks after U266-EGFP cell transplantation. Myeloma cells form a cellular complex with osteoblasts and osteoclasts in vivo.
Representative data from 10 to 20 fields from the BM of two mice from three independent experiments are shown. Bars=50 mm. B. Regional
differences in TRAP-positive osteoclast cells in the long bones. Micrographs of TRAP staining of the metaphysis and the diaphysis at 4 weeks after
U266-EGFP cell transplantation. Whereas the development of TRAP-positive osteoclast cells is barely discernable in the diaphysis region, a number of
TRAP-positive osteoclast cells are evident in the metaphysis region. The experiment was performed three times with similar results. Bars=200 mm.
doi:10.1371/journal.pone.0030557.g002
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+ cells (Fig. 6F). These data suggest that
bendamustine treatment affects not only myeloma cells but also
the surrounding niche cells.
Because myeloma often includes pathological myelofibrosis
[22], the effect of bendamustine on myelofibrosis was examined.
Moderate reticulin-positive fibrosis was noted in the non-treated
BM of thoracic vertebrae (Fig. 6G, left); however, no fibrosis was
observed in the BM of mice treated with a single dose of
bendamustine (Fig. 6G, right). Masson trichrome staining, which
detects collagen deposition, revealed several significant fibrotic
regions in the non-treated BM of thoracic vertebrae (Fig. 6H, left).
On the other hand, no collagen fibrosis was evident in the BM of
mice treated with a single dose of bendamustine (Fig. 6H, right).
These data indicate that bendamustine suppresses pathological
myelofibrosis in vivo.
Hematological maintenance by bendamustine
administration
Human IgE levels in the serum of mice receiving a single
bendamustine administration were significantly suppressed com-
pared to the non-treated group (Fig. 7A). In histological studies,
massive infiltration of myeloma cells was observed in the thoracic
vertebrae of non-treated mice, and normal hematopoiesis was
minimal (Fig. 7B, left). However, a number of normal hemato-
poietic cells, including megakaryocytes, were observed in the BM
of single bendamustine-administrated NOG mice (Fig. 7B, right).
Flow cytometric analysis of non-treated and bendamustine-treated
groups showed that the percentage of myeloma cells was decreased
in bendamustine-treated mice (Fig. 7C).
Bendamustine induces p53-dependent apoptosis and
suppresses myeloma cells in vivo
To clarify the molecular mechanism of bendamustine in vivo,
apoptotic activity was analyzed by detection of cleaved caspase-3.
In bendamustine-treated mice, the number of cleaved caspase-3
+
myeloma cells was significantly increased (Fig. 8A, B). Immuno-
cytochemical analysis of apoptosis-related proteins showed that the
levels of total and activated p53, a crucial participant in the
apoptotic pathway, were drastically increased in bendamustine-
treated myeloma cells (Fig. 8C–F). Although the level of Bax was
unchanged by bendamustine treatment (Fig. 8G, H), p21, which
induces cell cycle arrest preceding p53-dependent apoptosis, was
significantly increased in bendamustine-treated MM cells (Fig. 8I,
J).
Discussion
The present study contributes to the characterization of the
MM niche in the BM, which is still incompletely elucidated in vivo.
Here we show that MM cells preferentially engraft at the
metaphyseal region of the BM endosteum and form a complex
with osteoblasts and osteoclasts (Fig. 1F, G, 2A). The preferential
engraftment of MM cells at the metaphyseal region is thought to
be due to the abundance of vasculature in the metaphysis, which is
composed of trabecular-rich cancellous bone and a dense vascular
network made up of numerous sinusoid capillaries [23]. Similarly,
transplanted hematopoietic stem and progenitor cells (HSPC) also
engraft preferentially to the metaphysic [24,25], as do bone
metastases of several hematological malignancies [26] and solid
Figure 3. MM cells express VE-cadherin and form endothelial-like structures in the BM. A. Flow cytometric detection of VE-cadherin in
U266-EGFP cells in vitro (left) or transplanted U266-EGFP cells (right) using anti-human VE-cadherin antibody. The experiment was performed with
more than twenty mice with similar results. B. Triple IHC of GFP (green), human CD138 (gray) and VE-cadherin (red) within the diaphyseal region at 4
weeks after U266-EGFP cell transplantation. Representative data from four fields from the BM of three mice in two independent experiments are
shown. Bars=20 mm. C–E. Quantitative PCR analysis of IL-6 (B), VEGFA (C) or FGF-2 (D) transcripts in the VE-cadherin
+ or VE-cadherin
2 MM fractions
five weeks after U266-EGFP cell transplantation. Each value was normalized to b-actin expression and is expressed as the fold induction compared to
VE-cadherin
+ samples (mean 6 SD, **P,0.01, n=4). The experiment was performed twice with similar results.
doi:10.1371/journal.pone.0030557.g003
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important for the homing of transplanted HSPC or malignant cells
to the bone marrow.
VE-cadherin is a cell adhesion molecule that is crucial for tube
formation by endothelial cells [27]. Myeloma cells express
various angiogenic factors and promote angiogenesis in the BM.
In particular, VEGF [17], its receptors [28], and b-FGF [29] are
reportedly produced by MM cells. In this paper, MM cells were
also observed to express VE-cadherin, but only in vivo (Fig. 3A,
B). Since we observed a small population of bendamustine-
resistant myeloma cells that were positive for VE-cadherin
(Fig. 4E), similar events might occur in the MM in vivo.
Furthermore, the expression of HIF-2a was increased in VE-
cadherin
+ cells compared to the VE-cadherin
2 fraction in vivo or
to in vitro cultured MM cells (Fig. 4F). The retention of
pimonidazole and the expression level of HIF-1a were also
elevated in the VE-cadherin
+ cell fraction (Fig. 4G, H). These
results indicated that HIF-2aspecifically induced MM cells to
express VE-cadherin in the BM. This HIF-2a-VE-cadherin
pathway is activated in a subset of MM cells in response to
hypoxia and might contribute to the maintenance and drug
resistance of MM in vivo. A recent study has reported that
lenalidomide, which is approved for the treatment of MM and
myelodysplastic syndromes associated with deletion of the long
arm of chromosome 5q, inhibited hypoxia-induced endothelial
cell cord formation and HIF-1a accumulation [30]. lenalidomide
Figure 4. Bendamustine-treated MM cells remaining at the metaphyseal region express VE-cadherin and show hypoxic
phenotypes. A. A single dose of bendamustine (20 mg/kg) or an equivalent amount of PBS was administered intraperitoneally to engrafted
mice 5 days after U266-EGFP cell transplantation. Four to six weeks after administration, mice were sacrificed for analysis. B. Over the course of a
week, two sequential doses of bendamustine (20 mg/kg) or equivalent amounts of PBS were administered intraperitoneally to engrafted mice 5 days
after U266-EGFP cell transplantation. These mice were sacrificed for analysis when the mice had developed disease symptoms. C, D. IHC of human
CD138 (gray) at the diaphyseal region (C) or the metaphyseal region (D) at 4 weeks after treatment in bendamustine-treated mice (right panel) or
non-treated (PBS-treated) mice (left panel). Representative data from five fields of the BM of two mice per group in two independent experiments are
shown. In A and B, the left bars=200 mm, and in B, the right bar=100 mm. E. Double IHC of human CD138 (gray) and VE-cadherin (red) at 4 weeks
after treatment in bendamustine-treated mice. The arrows indicate human CD138-positive MM cells. Representative data from five fields of the BM of
two mice in two independent experiments are shown. Bar=50 mm. F–H. Quantification of HIF-2a (F) or HIF-1a (H) protein levels in cultured U266-
EGFP cells, or VE-cadherin
+ or VE-cadherin
2 fractions, 6 weeks after U266-EGFP cell transplantation and quantification of pimonidazole retention (G)
in VE-cadherin
+ or VE-cadherin
2 fractions at 6 weeks after transplantation. The experiment was performed twice with similar results. I. Human
CD138
+ mouse CD45
2 MM cells were sorted from non-treated or bendamustine-treated mice, and VEGFA, IL-6 or FGF-2 transcripts were examined by
qRT-PCR. Each value was normalized to b-actin expression (mean 6 SD, **P,0.01, n=4). The experiment was performed twice with similar results.
doi:10.1371/journal.pone.0030557.g004
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protein, b-catenin, in a dose-dependent manner [30]. Combi-
nation therapy including anti-angiogenic agents such as lenali-
domide may overcome the drug resistance in MM. Recently, the
stem cell-like fraction in glioblastoma has been shown to induce
a subset of VE-cadherin-expressing endothelial progenitors [31],
which form vascular-like structures [32] and maintain tumori-
genesis. Thus, the tumor derived or associated vascular cells
should be a target of cancer therapy.
During MM progression, in the metaphysical region of the BM,
increased numbers of osteoclasts were localized near to, and made
contact with, MM cells (Fig. 2B). Because inhibition of osteoclasts
reduces angiogenesis and tumor burden in MM [33], both
osteoclastogenesis and angiogenesis are considered to progress in
parallel to the growth of MM cells. Therefore, these histological
findings are in accordance with the current opinion that there is a
close relationship between progression of MM, osteoclast forma-
tion, and angiogenesis.
ECM proteins play a crucial role in hematopoietic stem cell
(HSC) regulation, especially as scaffold proteins [34]. Our
observation that ECM structure, especially fibronectin, was
increased and disorganized in the non-MM occupied diaphyseal
area (Fig. 5B) may indicate migration of MM cells from the
metaphysis to the diaphysis. Previous studies have reported that
binding MM cells with fibronectin protected MM cells from drug-
induced apoptosis [35,36]. Therefore, targeting not only tumor
cells but also the BM niche that sustains tumor growth and survival
is an effective treatment strategy for MM.
It is well known that osteoblasts are suppressed by MM cells
[37]. We observed disruption of the osteoblast lining on the bone
surface in MM mice (Fig. 6A), which suggested a functional
decline in osteoblasts, which differentiate from MSCs. It has been
reported that MM cells inhibit osteoblastogenesis by blocking the
differentiation capacity of mesenchymal and osteoprogenitor cells
[38]. According to these previous findings, the increased nestin
+
mesenchymal cells in the MM BM (Fig. 4G) could be a result of
Figure 5. Disorganized ECM components and increased mesenchymal cells in the MM niche. A, B. IHC of fibronectin (red; A), or
fibronectin (red) and human CD138 (gray; B), at the diaphyseal region (left) or metaphyseal region (right) of long bones of a non-transplanted NOG
mouse (A) or U266-EGFP cell-transplanted NOG mice (B). Representative data from five fields from the BM of one non-transplanted NOG mouse and
five U266-EGFP cell-transplanted mice in two independent experiments are shown. Bars=200 mm. C, D. IHC of type IV collagen (red; C), or type IV
collagen (red) plus human CD138 (gray; D), at the diaphyseal region (left) or metaphyseal region (right) of the long bones of a non-transplanted NOG
mouse (C) or U266-EGFP cell-transplanted NOG mice (D). Representative data from five fields from the BM of one non-transplanted NOG mouse and
five U266-EGFP cell-transplanted mice from two independent experiments are shown. Bars=200 mm. E, F. IHC of a-laminin (red; E), or a-laminin (red)
plus human CD138 (gray; F), at the diaphyseal region (left) or metaphyseal region (right) of the long bones of a non-transplanted NOG mouse (E)o r
U266-EGFP cell-transplanted NOG mice (F). Representative data from five fields from the BM of one non-transplanted NOG mouse and five U266-
EGFP cell-transplanted mice from two independent experiments are shown. Bars=200 mm. G. IHC of nestin (green; upper panel), or nestin (green)
plus human CD138 (gray; middle and lower panels), of the long bones of a non-transplanted NOG mouse (upper panel) or U266-EGFP cell-
transplanted NOG mice (middle and lower panels). Nestin
+ mesenchymal cells were rare in normal NOG BM (upper panel; arrow) but increased in
U266-EGFP cell-transplanted mice independent of vascular association (lower two panels). Representative images from five fields from the BM of one
non-transplanted NOG mouse and five U266-EGFP cell-transplanted mice from two independent experiments are shown. Bars=40 mm. (Magnified
figure bar=20 mm.) H. Triple IHC of nestin (green), CD138 (gray) and VE-cadherin (red) within the metaphyseal regions at 4 weeks after U266-EGFP
cell transplantation. Arrows indicate vessels. Representative data from 10 to 20 fields from the BM of two mice from three independent experiments
are shown. Bar=40 mm.
doi:10.1371/journal.pone.0030557.g005
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disease progression of MM. As nestin
+ mesenchymal cells produce
various chemokines and cytokines, the disruption of normal
hematopoiesis in MM pathophysiology might be caused by spatial
occupancy of tumor growth, disorganized ECM, or reductions in
HSC numbers, the latter of which may result from the reduction in
osteoblast numbers or from MSC signaling in a paracrine manner.
The present study also clarified the specific molecular effects of
bendamustine on MM cells and the MM niche using the NOG-
hMM model. Bendamustine reduced VEGF and IL-6 levels in the
NOG-hMM model (Fig. 4I). Any direct effects of bendamustine on
MM niche cells are not detected at this time, but our results
demonstrate that bendamustine could ameliorate MM-induced
dysregulation of the BM niche. Future studies will address the
direct and indirect effects of bendamustine on MM cells and MM
niche cells in the patients and further evaluation of neovascular
niches for MM in human samples.
In this study, the mice were not rescued from hind leg paralysis.
Nor was the condition of the already diseased mice improved by
bendamustine treatment. Bendamustine treatment only delayed
the onset of hind leg paralysis (data not shown). The result is
possibly due to the remaining MM cells being sufficient to induce
clinical symptoms, including hind leg paralysis. In future studies,
we will modify our hNOG-MM system by using fewer MM cells
for transplantation and a treatment protocol designed to improve
MM symptoms.
Figure 6. Bendamustine maintains the normal BM niche in vivo.A .Double IHC of human CD138 (red) and ALP (cyan) at 4 weeks after
treatment in bendamustine-treated mice (right panel) or non-treated mice (left panel). The arrows indicate the osteoblast lining on the bone surface.
Representative data from seven fields of the BM of two mice per group from two independent experiments are shown. Bars=60 mm. B.
Representative photomicrographs of TRAP staining of the metaphyseal region of the femur at 4 weeks after treatment in bendamustine-treated mice
(right panel) or non-treated mice (left panel). Representative data from three fields from the BM of four non-treated mice or two bendamustine-
treated mice from two independent experiments are shown. Bars=100 mm. C–E. Double IHC of fibronectin (red; C), type IV collagen (D)o ra-laminin
(E) with human CD138 (gray) at 4 weeks after bendamustine treatment. Representative data from five fields of the BM of two bendamustine-treated
mice from two independent experiments are shown. Bars=200 mm. F. Double IHC of nestin (green) and human CD138 (gray) at 4 weeks after
bendamustine treatment. Representative data from five fields of the BM of two bendamustine-treated mice from two independent experiments are
shown. Bar=40 mm. G. Histological studies of the thoracic vertebrae of NOG mice 4 weeks after treatment in bendamustine-treated mice (right
panel) or non-treated mice (no treatment; left panel). Reticulin staining: T, tumor; m, marrow. Representative data from five fields of the BM of five
mice per group from two independent experiments are shown.Bars=100 mm. H. Histological studies of the thoracic vertebrae of NOG mice 4 weeks
after treatment in bendamustine-treated mice (right panel) or non-treated mice (left panel). Masson trichrome staining: T, tumor; m, marrow.
Representative data from five fields of the BM of five mice per group from two independent experiments are shown. Bars=100 mm.
doi:10.1371/journal.pone.0030557.g006
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NOG-hMM model and examined the effects of bendamustine on
both myeloma cells and the surrounding microenvironment in vivo.
The vascular component of the MM niche plays an important role
in supporting MM cells, especially with regard to chemoresistance.
Interestingly, these results demonstrated that VE-cadherin
+ cells
Figure 7. Bendamustine suppresses MM cells in vivo.A .Serum levels of human IgE. Human IgE levels in the serum of NOG mice 4 weeks after
treatment with bendamustine were analyzed by ELISA. Non-treated mice were injected with PBS (n=5, mean 6 SD). The experiment was performed
three times with similar results. B. Histological studies of the thoracic vertebrae of NOG mice 4 weeks after treatment with bendamustine (right panel)
or non-treatment (left panel). Massive infiltration of U266-EGFP cells was observed in non-treated mice. However, an overall reduction of U266-EGFP
cells and maintenance of normal hematopoiesis were observed in bendamustine-treated mice. HE staining: T, tumor; m, marrow; arrow,
megakaryocyte. Representative data from five fields from the BM of five mice per group from two independent experiments are shown. Upper panel
bars=200 mm. Lower panel bars=100 mm. C. FACS analysis of U266-EGFP cells at 4 weeks after treatment in bendamustine-treated or non-treated
mice (n=5, mean 6 SD). Representative FACS plots of at least 10 mice from two independent experiments are shown.
doi:10.1371/journal.pone.0030557.g007
Figure 8. Bendamustine induces p53-dependent apoptosis. Human CD138
+ mouse CD45
2 MM cells from non-treated or bendamustine-
treated mice were sorted and immunocytochemistry was performed to analyze cleaved caspase-3 (A, B), p53 (C, D), phosphorylated-p53 (E, F), Bax
(G, H), and p21 (I, J). Each group of MM cells was stained with DAPI and anti-fibronectin antibody, anti-p53 antibody, anti-phosphorylated-p53
antibody, anti-Bax antibody, or anti-p21 antibody. At least 100 cells/sample were counted (mean 6 SD, n=10). Bars=50 mm.
doi:10.1371/journal.pone.0030557.g008
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and bortezomib [41] have all been shown to have anti-angiogenic
effects. However, these agents have not been sufficient for the
effective treatment of MM. The drug-resistant hypoxic VE-
cadherin
+ HIF-2a
+ MM fraction identified in this model presents a
candidate target for the adjustment of bendamustine dose,
combination therapy, or selective targeting (Fig. 9). The NOG-
hMM model described here is a useful system for the analysis of
the in vivo dynamics and kinetics of myeloma cell pathophysiology
and for observing the interactions of MM cells with other
components of the microenvironment, as well as for the
development of novel anti-MM therapies.
Materials and Methods
Mice
NOG (NOD/SCID/cc
null) mice [12] were purchased from the
Central Institute for Experimental Animals. All animal experi-
ments were approved by the Keio University School of Medicine’s
ethical review board (approval ID: 08104).
Reagents and antibodies
Bendamustine was kindly provided by SymBio Pharmaceuticals
Ltd. The following antibodies (Abs) labeled with fluorophores were
used for flow cytometric analysis and cell sorting: anti-mouse
CD45 (30-F11; BD Biosciences), anti-human CD138 (BD
Biosciences), and anti-human VE-cadherin (16B1; eBioscience).
For immunohistochemical staining of BM sections or immunocy-
tochemical staining of MM cells, the following Abs were used:
mouse anti-CD138 (AbD seroTec), rabbit anti-ALP (R&D), anti-
MMP9 (Chemicon), anti-GFP (MBL), rabbit anti-fibronectin
(Dako), rabbit anti-type IV collagen (AbD seroTec), rabbit anti-
a-laminin (Sigma), rat anti-nestin (BioAcademia), FITC-conjugat-
ed anti-pimonidazole (Chemicon), rabbit anti-HIF-1a (Santa
Cruz), and rabbit anti-HIF-2a (Santa Cruz).
Quantitative RT-PCR
Quantitative PCR was performed as described previously [42].
Total RNA was prepared with the RNeasy Mini Kit (Qiagen) and
was reverse-transcribed with Superscript VILO (Invitrogen) to
prepare cDNA. Diluted cDNA samples were analyzed with SYBR
Premix Ex Taq II (TaKaRa) using readymade primer sets for each
gene (TaKaRa), according to the manufacturer’s instructions.
Primer sets were used for human IL-6 (HA032507), VEGFA
(HA110047), FGF-2 (HA035991), or b-actin (HA031582), which
served as an endogenous control. Data were analyzed using 7500
Fast System SDS software, version 1.3.1.
Human MM model
The human myeloma cell line, U266, was purchased from the
American Tissue Culture Collection (Manassas, VA [13]; and was
stably tagged with EGFP with a lentiviral vector. 2610
6 U266-
EGFP cells were intravenously inoculated into irradiated NOG
mice (2.4 Gy). After transplantation, mice were given sterile water
containing hydrochloric acid and G418 disulfate in aqueous
solution (Nacalai Tesque).
Flow cytometry
Stained cells were analyzed and sorted on a SORP FACS Aria
(BD Biosciences).
Immunohistochemistry
Femurs were fixed in 4% paraformaldehyde, decalcified in
EDTA, and embedded in OCT. Frozen sections were cut using a
cryostat (MICROME, model HM550). Slides were washed three
Figure 9. Anti-MM effects of bendamustine on MM cells and the BM niche. MM interacts with several BM microenvironments (A). Within the
MM BM niche, bendamustine affects both MM cells and the surrounding niche in vivo (B). OBs, osteoblast cells; OCs, osteoclast cells.
doi:10.1371/journal.pone.0030557.g009
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Ltd.). For immunohistochemistry, femoral frozen sections were
washed three times in PBS, blocked with a protein blocker
(DAKO), and then incubated with primary antibodies overnight in
humidified chambers at 4uC. The sections were then washed three
times in PBS and reacted with fluorophore-labeled secondary
antibodies and a nuclear stain (TOTO3 or DAPI; Molecular
Probes). Fluorescence images were obtained using a confocal laser-
scanning microscope (FV1000; Olympus) in the linear range to
avoid fluorescence saturation. Scanning was performed in the
sequential laser emission mode to avoid cross-talk between the
fluorescence channels. For detection of cellular hypoxia, six weeks
after MM cell transplantation, NOG mice were injected with
60 mg/kg pimonidazole (Pimo; Chemicon) 90 min before sacri-
fice. Human CD138-gated VE-cadherin–positive or –negative
fractions were sorted for immunocytochemistry.
Histological evaluation
Thoracic vertebra were fixed in 4% PFA and decalcified in
EDTA, followed by paraffin embedding and sectioning. Morpho-
logical evaluation of the sections was performed following
hematoxylin and eosin (HE) staining, reticulin staining, and
Masson trichrome staining.
Human IgE measurement
Serum levels of human IgE in NOG recipients was measured
using a human IgE ELISA kit (Phadia, SW) following the
manufacturer’s instructions.
Statistical analysis
P-values were calculated using two-tailed unpaired Student’s t-
tests (for experiments with normal distribution), Wilcoxon tests (for
two-group experiments with non-normal distribution), or Tukey’s
multiple comparison tests (for multiple-group experiments).
Supporting Information
Table S1 U266-GFP cells rarely fused with mouse
endothelial cells. Fluorescence in situ hybridization (FISH)
analysis of VE-cadherin positive and VE-cadherin negative cell
fractions, and cultured U266-GFP cells. Each fusion rate is
represented.
(PDF)
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